NCT02153502 - Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

DRUG

AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)

AVP-786 capsules administered twice a day over a 10-week period

DRUG

Placebo

Placebo capsules administered twice a day over a 10-week period

Trial Locations (32)

10003

New York

10312

Staten Island

11241

Brooklyn

19104

Philadelphia

19139

Philadelphia

21061

Glen Burnie

21285

Baltimore

30030

Decatur

32256

Jacksonville

32763

Orange City

32801

Orlando

33155

Miami

34201

Bradenton

35213

Birmingham

35294

Birmingham

44125

Garfield Heights

46383

Valparaiso

60169

Hoffman Estates

73103

Oklahoma City

73112

Oklahoma City

74101

Tulsa

80239

Denver

84123

Murray

90706

Bellflower

90717

Lomita

91403

Sherman Oaks

92056

Oceanside

92506

Riverside

92626

Costa Mesa

92706

Santa Ana

92845

Garden Grove

02131

Boston